Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amyotrophic Lateral Sclerosis
Phase II trial for ALS expected to begin after second quarter
July 24th, 2005
CytRx Corp. (CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics primarily in the area of small molecules and ribonucleic acid interference, announced it has submitted a reply to a request for additional information from the U.S. Food and Drug Administration (FDA) related to the company's investigational new drug (IND) application for arimoclomol for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. CytRx announced filing of the IND on May 23, 2005, and submitted the additional documents requested by the FDA recently. Receipt by the FDA of the company's response will trigger a...
Source: Medical Letter on the CDC & FDA (2005-07-24)
|
